One Year After Securing API License for Pharma Grade CBD, Folium Biosciences Reports Broad Global Pharmaceutical Adoption
Susie Caldwell Hays*
Distinguished Executive, Folium Biosciences, USA.
*Corresponding Author
Susie Caldwell Hays,
Distinguished Executive, Folium Biosciences, USA.
E-mail: susie@q2mark.com
Received: October 16, 2020; Accepted: November 04, 2020; Published: December 17, 2020
Citation:Susie Caldwell Hays. One Year After Securing API License for Pharma Grade CBD, Folium Biosciences Reports Broad Global Pharmaceutical Adoption. Int J Life Sci Res Dev. 2020;2(1):10.
Copyright: Susie Caldwell Hays©2020. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Folium’s CBD API is an essential ingredient in pharmaceutical formulations worldwide.
Colorado Springs, Colo. – October 15, 2020 – Since securing its Active Pharmaceutical Ingredient (API) license one year ago, Folium Biosciences’ CBD Isolate has been widely adopted for pharmaceutical formulations worldwide in countries with stringent cannabinoid regulations - including Japan, Australia, New Zealand, and South America.
“Our pharmaceutical partners rely on us not only for superior CBD ingredients, but also for our unique knowledge of the pharmaceutical product development process,” says Folium Chief ScienceOfficer Dr. M.V. Fernandez Cid. “More than a supplier, we are a developmentpartner. Our team has been conducting clinical research in cannabinoids since the start of the industry, which means that we understand exactly what a pharmaceutical company needs to have in place when it comes to securing approvals from global ethical commissions and regulatory bodies. We believe that critical insight and experience is as essential to CBD product success as is our unrivaled quality.”
Folium Biosciences is one of only a few companies that are approved to provide the international pharmaceutical industry with active ingredients for the development of CBD-based drugs. Folium’s CBD API is produced at the company’s cannabis-licensed subsidiary,Folium Biosciences Europe B.V.,which is developing a pipeline of cannabinoid APIs including dronabinol (THC) and CBG that are currently in the validation phase.
About Folium
Headquartered in Colorado Springs, Colo., Folium Biosciences is
a vertically integrated B2B producer, manufacturer, and distributor
of hemp-derived non-psychoactive cannabinoidsand FDAapproved
pharmaceutical ingredients. Built on the core tenets of
quality, science, scale, and innovation, Folium Biosciences controls
all aspects of the supply chain from genetics and extraction
to bulk and finished products. Folium Biosciences’ team of
scientists, chemists, engineers, and other committed professionals
delivers the world’s highest-quality hemp-derived non-psychoactive
cannabinoids and FDA-approved pharmaceutical ingredients
through a proprietary process, resulting in a THC content
of 0.0%. Folium Biosciences was the first hemp company to be
issued a Certificate of Free Sale and a Manufactured Food Establishment
License by the Colorado Department of Public Health
and Environment and continues to lead the industry in regulatory
compliance and governance.
